Biostax Quick Ratio (BTAX) starting from the third quarter 2024 to third quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Biostax Corp  (BTAX)

Biostax's Quick Ratio

BTAX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2024, Quick Ratio fell to 0 a new company low.

Within Major Pharmaceutical Preparations industry 482 other companies have achieved higher Quick Ratio than Biostax in third quarter 2024. While Quick Ratio total ranking in the third quarter 2024 has deteriorated compared to the prior quarter from 4371 to 4704.

Explain Quick Ratio?
How much Cash & cash equivalents BTAX´s has?
What are BTAX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BTAX Quick Ratio (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3
Y / Y Current Liabilities Change 26.53 % 37.48 % 36.52 % 31.23 % 50.79 %
Y / Y Cash & cash equivalent Change -45.17 % -76.22 % -84.04 % -82.46 % -94.75 %
Quick Ratio MRQ 0 0 0 0.01 0
BTAX's Total Ranking # 4704 # 4371 # 4025 # 3841 # 3973
Seq. Current Liabilities Change 0.4 % 8.72 % 7 % 8.34 % 9.09 %
Seq. Cash & cash equivalent Change 0.9 % -28.26 % -78.47 % 251.76 % -56.25 %



Quick Ratio third quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 483
Healthcare Sector # 1009
Overall Market # 4704


Quick Ratio Statistics
High Average Low
0.17 0.02 0
(Dec 31 2013)   (Jun 30 2018)




Financial Statements
Biostax's Current Liabilities $ 5 Millions Visit BTAX's Balance sheet
Biostax's Cash & cash equivalent $ 0 Millions Visit BTAX's Balance sheet
Source of BTAX's Sales Visit BTAX's Sales by Geography


Cumulative Biostax's Quick Ratio

BTAX's Quick Ratio for the trailling 12 Months

BTAX Quick Ratio

 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth 32.77 % 38.36 % 4.98 % -33.6 % -52.77 %
Y / Y Cash & cash equivalent TTM Growth -80.9 % -87.39 % -89.34 % -89.47 % -79.78 %
Quick Ratio TTM 0 0 0 0.01 0.02
Total Ranking TTM # 3917 # 3520 # 3378 # 3333 # 3372
Seq. Current Liabilities TTM Growth 5.89 % 8.26 % 8.06 % 7.18 % 10.35 %
Seq. Cash & cash equivalent TTM Growth -7.76 % -23.04 % -34.53 % -58.89 % -39.1 %

Quick ratio ranking by company, industry and sector >> Back to BTAX Financial Strength Comparisons >> Go to Compare BTAX Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the rise in Current Liabilities in the Q3 2024 to $5.33 millions, cumulative Quick Ratio